

# Laurent CastÃ©ra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2614371/publications.pdf>

Version: 2024-02-01

96  
papers

14,751  
citations

41344

49  
h-index

38395

95  
g-index

103  
all docs

103  
docs citations

103  
times ranked

12287  
citing authors

#	ARTICLE	IF	CITATIONS
1	5â€™2 Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints. <i>Cancers</i> , 2021, 13, 3171.	3.7	5
2	Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. <i>American Journal of Human Genetics</i> , 2021, 108, 1907-1923.	6.2	14
3	Full in-frame exon 3 skipping of <i>BRCA2</i> confers high risk of breast and/or ovarian cancer. <i>Oncotarget</i> , 2018, 9, 17334-17348.	1.8	24
4	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, e16-e47.	1.5	659
5	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, 377-394.	1.5	93
6	<scp>EASL</scp> and <scp>AASLD</scp> recommendations for the diagnosis of <scp>HCC</scp> to the test of daily practice. <i>Liver International</i> , 2017, 37, 1515-1525.	3.9	102
7	Screening studies of transient elastography and FibroTest in the general population â€™ Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246-247.	8.1	0
8	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. <i>Clinical Cancer Research</i> , 2017, 23, 2750-2758.	7.0	31
9	Farewell from the EASL Secretary General. <i>Journal of Hepatology</i> , 2017, 66, 873-874.	3.7	0
10	Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?. <i>Journal of Hepatology</i> , 2017, 66, 304-312.	3.7	8
11	Non-invasive diagnosis of hepatic steatosis. <i>Hepatology International</i> , 2017, 11, 70-78.	4.2	101
12	Joint Society Statement for elimination of viral hepatitis. <i>Annals of Hepatology</i> , 2017, 16, 6-7.	1.5	4
13	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	8.1	131
14	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. <i>Hepatology</i> , 2016, 63, 138-147.	7.3	253
15	Joint society statement for the elimination of viral hepatitis. <i>Journal of Hepatology</i> , 2016, 65, 661-662.	3.7	2
16	Joint society statement for the elimination of viral hepatitis. <i>Hepatology</i> , 2016, 64, 1031-1032.	7.3	5
17	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1491-1500.	2.4	31
18	Critical comparison of elastography methods to assess chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 402-411.	17.8	198

#	ARTICLE	IF	CITATIONS
19	We will not rest on our laurels!. Journal of Hepatology, 2016, 64, 8-9.	3.7	0
20	Non-invasive tests for liver fibrosis progression and regression. Journal of Hepatology, 2016, 64, 232-233.	3.7	13
21	Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease, 2015, 6, 5-8.	2.1	16
22	Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. Cancer Medicine, 2015, 4, 1484-1493.	2.8	35
23	Assessing liver disease in HIV-HCV coinfecting patients. Current Opinion in HIV and AIDS, 2015, 10, 316-322.	3.8	8
24	Is it really worth adapting liver stiffness cut-offs according to <scp>AST</scp> levels?. Liver International, 2015, 35, 2495-2497.	3.9	4
25	Diagnosis of Liver Fibrosis: Present and Future. Seminars in Liver Disease, 2015, 35, 166-183.	3.6	49
26	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 2: Breast. Ultrasound in Medicine and Biology, 2015, 41, 1148-1160.	1.5	368
27	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. Journal of Hepatology, 2015, 62, 848-854.	3.7	228
28	Characterization of fortuitously discovered focal liver lesions: additional information provided by shearwave elastography. European Radiology, 2015, 25, 346-358.	4.5	44
29	Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno VI consensus". Journal of Hepatology, 2015, 63, 1049-1050.	3.7	5
30	Noninvasive Assessment of Liver Fibrosis. Digestive Diseases, 2015, 33, 498-503.	1.9	44
31	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 1: Basic Principles and Terminology. Ultrasound in Medicine and Biology, 2015, 41, 1126-1147.	1.5	718
32	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver. Ultrasound in Medicine and Biology, 2015, 41, 1161-1179.	1.5	620
33	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver International, 2015, 35, 2466-2473.	3.9	24
34	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 291-303.	3.6	65
35	Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. Radiology, 2015, 275, 589-598.	7.3	190
36	FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clinical Gastroenterology and Hepatology, 2015, 13, 27-36.	4.4	133

#	ARTICLE	IF	CITATIONS
37	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified) Tj ETQq1 1 0.784314 rgBT /Overlook Hepatocellular Carcinoma Treated With Sorafenib. Oncologist, 2014, 19, 394-402.	3.7	134
38	Radioembolisation with yttriumâ€™90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials, 2014, 15, 474.	1.6	38
39	Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. European Radiology, 2014, 24, 1394-402.	4.5	103
40	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. European Journal of Human Genetics, 2014, 22, 1305-1313.	2.8	217
41	Hepatitis B: are nonâ€™invasive markers of liver fibrosis reliable?. Liver International, 2014, 34, 91-96.	3.9	50
42	Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 666-675.	17.8	238
43	Update on ultrasound imaging of liver fibrosis. Journal of Hepatology, 2013, 59, 180-182.	3.7	87
44	Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact. Journal of Vascular and Interventional Radiology, 2013, 24, 1623-1631.	0.5	9
45	When the Spleen Gets Tough, the Varices Get Going. Gastroenterology, 2013, 144, 19-22.	1.3	46
46	Non invasive evaluation of portal hypertension using transient elastography. Journal of Hepatology, 2012, 56, 696-703.	3.7	289
47	Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. Gastroenterology, 2012, 142, 1293-1302.e4.	1.3	533
48	How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?. Liver International, 2011, 31, 13-17.	3.9	56
49	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 291-303.	2.4	119
50	Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatology International, 2011, 5, 625-634.	4.2	72
51	Screening the general population for cirrhosis using transient elastography: finding a needle in a haystack?. Gut, 2011, 60, 883-884.	12.1	8
52	Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. Hepatology, 2010, 51, NA-NA.	7.3	890
53	Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. Journal of Hepatology, 2010, 52, 191-198.	3.7	188
54	Diagnosing cirrhosis non-invasively: Sense the stiffness but donâ€™t forget the nodules!. Journal of Hepatology, 2010, 52, 786-787.	3.7	1

#	ARTICLE	IF	CITATIONS
55	Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. <i>Journal of Hepatology</i> , 2010, 53, 630-638.	3.7	123
56	Non-invasive assessment of liver fibrosis: are we ready?. <i>Lancet</i> , The, 2010, 375, 1419-1420.	13.7	118
57	Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. <i>Gut</i> , 2010, 59, 861-866.	12.1	182
58	Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1083-1089.	7.3	201
59	The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. <i>Hepatology</i> , 2009, 49, 1397-1398.	7.3	44
60	SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.	7.3	151
61	Liver stiffness and hepatocellular carcinoma: Liaisons dangereuses?. <i>Hepatology</i> , 2009, 49, 1793-1794.	7.3	12
62	Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2009, 16, 300-314.	2.0	146
63	Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. <i>Journal of Hepatology</i> , 2009, 50, 59-68.	3.7	340
64	Interpreting liver stiffness in the cirrhotic range: What are we measuring?. <i>Journal of Hepatology</i> , 2009, 50, 424-425.	3.7	2
65	Transient elastography vs. blood tests for the diagnosis of cirrhosis: An empiric victory. <i>Journal of Hepatology</i> , 2009, 51, 229.	3.7	0
66	Non-invasive evaluation of liver fibrosis using transient elastography. <i>Journal of Hepatology</i> , 2008, 48, 835-847.	3.7	1,170
67	Assessing liver fibrosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 541-552.	3.0	37
68	Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort. <i>American Journal of Gastroenterology</i> , 2008, 103, 1973-1980.	0.4	63
69	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. <i>Clinical Chemistry</i> , 2007, 53, 1615-1622.	3.2	227
70	Influence of heat stress on human monocyte-derived dendritic cell functions with immunotherapeutic potential for antitumor vaccines. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1179-1187.	3.3	38
71	Liver Stiffness Measurement in Children Using FibroScan: Feasibility Study and Comparison With Fibrotest, Aspartate Transaminase to Platelets Ratio Index, and Liver Biopsy. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 45, 443-450.	1.8	215
72	Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 168-173.	2.1	28

#	ARTICLE	IF	CITATIONS
73	Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines?. Journal of Hepatology, 2007, 46, 528-529.	3.7	84
74	Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years). Journal of Hepatology, 2007, 46, 19-25.	3.7	27
75	Reply:. Hepatology, 2007, 46, 282-283.	7.3	5
76	Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterology, 2007, 7, 40.	2.0	268
77	HEPACOM : multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-naïve patients managed in the French health care system. Gastroenterologie Clinique Et Biologique, 2007, 31, 1074-1080.	0.9	7
78	Hepatitis B virus genotypes : a retrospective survey in Southwestern France, 1999-2004. Gastroenterologie Clinique Et Biologique, 2007, 31, 1088-1094.	0.9	18
79	Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. European Journal of Gastroenterology and Hepatology, 2006, 18, 411-412.	1.6	331
80	Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterologie Clinique Et Biologique, 2006, 30, 189-195.	0.9	12
81	FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology, 2006, 43, 373-374.	7.3	44
82	Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology, 2006, 44, 1511-1517.	7.3	454
83	Dynamics of Hepatitis B Virus Resistance to Lamivudine. Journal of Virology, 2006, 80, 643-653.	3.4	88
84	Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. European Journal of Gastroenterology and Hepatology, 2005, 17, 179-184.	1.6	139
85	Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins. Journal of Medical Virology, 2005, 76, 279-284.	5.0	8
86	Occult Hepatitis B Virus Infection in HIV-Infected Patients with Isolated Antibodies to Hepatitis B Core Antigen: Aquitaine Cohort, 2002-2003. Clinical Infectious Diseases, 2005, 40, 750-753.	5.8	55
87	Hepatitis C Virus-Induced Hepatocellular Steatosis. American Journal of Gastroenterology, 2005, 100, 711-715.	0.4	70
88	Psychosocial Factors Associated With Perceived Disease Severity in Patients With Chronic Hepatitis C: Relationship With Information Sources and Attentional Coping Styles. Psychosomatics, 2005, 46, 25-33.	2.5	30
89	Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005, 128, 343-350.	1.3	2,216
90	The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis, 2004, 25, 1443-1448.	2.8	55

#	ARTICLE	IF	CITATIONS
91	Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2004, 72, 46-51.	5.0	6
92	Antiviral action of ribavirin in chronic hepatitis C. <i>Gastroenterology</i> , 2004, 126, 703-714.	1.3	261
93	Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. <i>Hepatology</i> , 2002, 35, 978-979.	7.3	43
94	Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: A randomized placebo-controlled trial. <i>American Journal of Gastroenterology</i> , 2001, 96, 1553-1557.	0.4	44
95	Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2000, 32, 412-418.	3.7	55
96	Macrovesicular steatosis induced by interferon alfa therapy for chronic myelogenous leukaemia. <i>Liver International</i> , 1999, 19, 259-260.	3.9	10